Patent ID: 7700299

Claim:
A method of predicting the response of a metastatic breast cancer patient to treatment with pertuzumab comprising the steps of: (a) determining the amount of each of the following biomarkers in a biological sample from a metastatic breast cancer patient that has been treated with pertuzumab: (1) the amino acid sequence of SEQ ID NO: 1; (2) the amino acid sequence of SEQ ID NO: 2; (3) the amino acid sequence of SEQ ID NO: 3; and (4) the amino acid sequence consisting of residues 22 to 645 of SEQ ID NO: 4; (b) determining whether the amount assessed in step (a) is above or below a quantity that is associated with an increased or decreased clinical benefit to a metastatic breast cancer patient; and (c) predicting the response to the treatment with pertuzumab in the patient by evaluating the results of step (b).